About
Technology
Issues
FAQ
Search
Profile
Schools
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Scientometrics
Avg. Impact Factor
Discipline Ranks
h
-index
g
-index
★★
Articles
★★★
Articles
Article Citations
Citation Distribution
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Institutions
›
General University Hospital in Prague
›
top-articles
General University Hospital in Prague
8
(top 1%)
papers
815
(top 1%)
citations
5
(top 1%)
h
-index
7
(top 1%)
g
-index
11
all documents
845
doc citations
312
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Lancet Oncology, The
2016
723
2
Intermittent hemodialysis is superior to continuous veno-venous hemodialysis/hemodiafiltration to eliminate methanol and formate during treatment for methanol poisoning
Kidney International
2014
70
3
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology
2019
15
4
Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.
Journal of Clinical Oncology
2015
14
5
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Journal of Clinical Oncology
2016
13
6
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Journal of Clinical Oncology
2016
5
7
P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
HemaSphere
0
4
8
Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).
Journal of Clinical Oncology
2016
1
9
Day Program for Patients with Brain Injury with Constraint Induced Movement Therapy for Upper and Lower Limbs
Biosystems and Biorobotics
2019
0
10
S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL
HemaSphere
0
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.